October 19, 2020 -- Cell therapeutics company Akron Biotechnology and respirator drug development firm Synairgen have partnered to advance interferon-beta (IFN-beta) treatment for patients with COVID-19.
The partnership will leverage SNG001, Synairgen's inhaled IFN-beta COVID-19 candidate. Synairgen reported positive results and safety, biomarker, and efficacy data from a phase II trial of the candidate in 101 patients hospitalized with COVID-19 this summer.
As part of the partnership, Akron Biotech will provide current good manufacturing practices (cGMP)-compliant solutions to aid in developing and commercializing Synairgen's candidate. The partnership leverages Akron's recombinant protein manufacturing expertise and large-scale production capacity to rapidly scale SNG001 production, the companies noted.
Financial terms of the deal were not disclosed.